semaglutide patent expiry us 2031 2026-2031 Semaglutide patent expiry opens door

No head-to-head randomized controlled trial comparing Retatrutide vs Tirzepatide directly has been published as of 2026, making direct efficacy comparisons inferential based on cross-trial data

When taken for weight loss as Zepbound or Mounjaro (off-label), studies have shown that people can lose an average of 21% of body weight over time

[3] [4] Keep pens away from children and pets , storing them in a secure location

Contiene semaglutida, un agonista del receptor GLP-1 que acta sobre los mecanismos naturales de regulacin del apetito, ayudando a disminuir el hambre y aumentar la sensacin de plenitud despus de las comidas